Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Coronary Stenosis | 6 | 2019 | 273 | 2.45 | Why? |
| Cardiomyopathy, Dilated | 2 | 2018 | 251 | 1.12 | Why? |
| Absorbable Implants | 7 | 2019 | 191 | 1.01 | Why? |
| Aortic Valve Stenosis | 4 | 2019 | 741 | 0.98 | Why? |
| Defibrillators, Implantable | 3 | 2018 | 624 | 0.97 | Why? |
| Transcatheter Aortic Valve Replacement | 4 | 2019 | 839 | 0.93 | Why? |
| Stents | 3 | 2018 | 916 | 0.92 | Why? |
| Takotsubo Cardiomyopathy | 2 | 2019 | 453 | 0.92 | Why? |
| Muscle, Smooth, Vascular | 2 | 2018 | 86 | 0.89 | Why? |
| Myocytes, Smooth Muscle | 2 | 2018 | 127 | 0.85 | Why? |
| Acute Coronary Syndrome | 7 | 2021 | 2107 | 0.83 | Why? |
| Coronary Restenosis | 2 | 2018 | 153 | 0.80 | Why? |
| Carotid Arteries | 2 | 2018 | 182 | 0.77 | Why? |
| Neointima | 2 | 2018 | 39 | 0.76 | Why? |
| Brugada Syndrome | 2 | 2018 | 98 | 0.76 | Why? |
| Hemorheology | 1 | 2018 | 17 | 0.74 | Why? |
| Fractional Flow Reserve, Myocardial | 2 | 2018 | 173 | 0.74 | Why? |
| Hindlimb | 1 | 2018 | 21 | 0.74 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.72 | Why? |
| RNA, Untranslated | 2 | 2018 | 140 | 0.72 | Why? |
| Foreign-Body Migration | 1 | 2017 | 25 | 0.70 | Why? |
| Percutaneous Coronary Intervention | 8 | 2018 | 3646 | 0.70 | Why? |
| Bites and Stings | 1 | 2019 | 91 | 0.68 | Why? |
| Drug-Eluting Stents | 6 | 2019 | 562 | 0.67 | Why? |
| Coronary Artery Disease | 5 | 2018 | 2570 | 0.66 | Why? |
| Blood Vessels | 1 | 2018 | 228 | 0.64 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.63 | Why? |
| Everolimus | 5 | 2019 | 215 | 0.63 | Why? |
| Cardiologists | 1 | 2021 | 366 | 0.63 | Why? |
| Education | 1 | 2021 | 434 | 0.62 | Why? |
| Coronary Vessels | 3 | 2018 | 914 | 0.61 | Why? |
| Femoral Artery | 1 | 2017 | 213 | 0.60 | Why? |
| Vasodilation | 1 | 2018 | 258 | 0.60 | Why? |
| MicroRNAs | 4 | 2018 | 1787 | 0.60 | Why? |
| Foramen Ovale, Patent | 1 | 2018 | 153 | 0.58 | Why? |
| Foreign Bodies | 1 | 2018 | 171 | 0.57 | Why? |
| Aortic Valve | 2 | 2018 | 664 | 0.56 | Why? |
| Coronary Thrombosis | 2 | 2019 | 433 | 0.56 | Why? |
| Paracrine Communication | 1 | 2014 | 73 | 0.53 | Why? |
| Mitral Valve Insufficiency | 1 | 2018 | 302 | 0.53 | Why? |
| Cardiomegaly | 1 | 2014 | 96 | 0.52 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.48 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2021 | 994 | 0.47 | Why? |
| Catheter Ablation | 1 | 2017 | 438 | 0.47 | Why? |
| Cardiology | 3 | 2021 | 2873 | 0.45 | Why? |
| Myocytes, Cardiac | 2 | 2017 | 804 | 0.45 | Why? |
| Cardiac Catheterization | 2 | 2018 | 882 | 0.44 | Why? |
| Coronary Artery Bypass | 1 | 2017 | 629 | 0.43 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.43 | Why? |
| Myocardial Infarction | 8 | 2020 | 3361 | 0.42 | Why? |
| Endothelial Cells | 2 | 2018 | 2048 | 0.42 | Why? |
| Fibroblasts | 1 | 2014 | 839 | 0.40 | Why? |
| Electrocardiography | 3 | 2019 | 3957 | 0.39 | Why? |
| Ischemia | 1 | 2018 | 901 | 0.39 | Why? |
| Heart Ventricles | 1 | 2018 | 1139 | 0.38 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.37 | Why? |
| Tissue Scaffolds | 3 | 2019 | 174 | 0.35 | Why? |
| Heart Valve Prosthesis | 3 | 2018 | 533 | 0.35 | Why? |
| Exosomes | 1 | 2014 | 567 | 0.35 | Why? |
| Cardiac Surgical Procedures | 2 | 2018 | 1931 | 0.34 | Why? |
| Consensus | 1 | 2021 | 6345 | 0.31 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.30 | Why? |
| ST Elevation Myocardial Infarction | 2 | 2019 | 3051 | 0.30 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.28 | Why? |
| Coronary Angiography | 6 | 2019 | 2275 | 0.27 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.26 | Why? |
| Plaque, Atherosclerotic | 2 | 2018 | 423 | 0.25 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.25 | Why? |
| Rats | 4 | 2018 | 2764 | 0.24 | Why? |
| Rats, Wistar | 3 | 2018 | 621 | 0.21 | Why? |
| Internship and Residency | 1 | 2021 | 4987 | 0.21 | Why? |
| Balloon Valvuloplasty | 1 | 2019 | 49 | 0.20 | Why? |
| Societies, Medical | 3 | 2021 | 6907 | 0.20 | Why? |
| Disease Vectors | 1 | 2021 | 208 | 0.19 | Why? |
| Coronary Care Units | 1 | 2021 | 224 | 0.19 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2018 | 10649 | 0.19 | Why? |
| rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2018 | 1 | 0.19 | Why? |
| Italy | 8 | 2021 | 38444 | 0.19 | Why? |
| Multipotent Stem Cells | 1 | 2017 | 9 | 0.18 | Why? |
| Mechanical Phenomena | 1 | 2018 | 50 | 0.18 | Why? |
| Heart Function Tests | 1 | 2018 | 101 | 0.18 | Why? |
| Heart Failure | 6 | 2021 | 6638 | 0.18 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.18 | Why? |
| Integrases | 1 | 2017 | 17 | 0.18 | Why? |
| Septal Occluder Device | 1 | 2018 | 46 | 0.18 | Why? |
| Humans | 43 | 2021 | 930598 | 0.18 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 59 | 0.17 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.17 | Why? |
| Echocardiography | 4 | 2019 | 3661 | 0.17 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.17 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.17 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.17 | Why? |
| Adult Stem Cells | 1 | 2017 | 68 | 0.17 | Why? |
| Watchful Waiting | 1 | 2019 | 276 | 0.17 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.17 | Why? |
| Genetic Markers | 1 | 2018 | 318 | 0.17 | Why? |
| Regeneration | 2 | 2018 | 429 | 0.17 | Why? |
| Circulating MicroRNA | 1 | 2018 | 123 | 0.16 | Why? |
| Prosthesis Failure | 1 | 2018 | 195 | 0.16 | Why? |
| Magnetic Resonance Angiography | 1 | 2018 | 282 | 0.16 | Why? |
| Heart Valve Diseases | 1 | 2021 | 355 | 0.16 | Why? |
| Biocompatible Materials | 1 | 2018 | 214 | 0.16 | Why? |
| Animals | 10 | 2021 | 78931 | 0.16 | Why? |
| Graft Occlusion, Vascular | 1 | 2017 | 105 | 0.15 | Why? |
| Coronary Circulation | 1 | 2018 | 188 | 0.15 | Why? |
| Stem Cells | 3 | 2018 | 595 | 0.15 | Why? |
| Polysomnography | 1 | 2017 | 296 | 0.15 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2021 | 490 | 0.15 | Why? |
| Device Removal | 1 | 2017 | 221 | 0.15 | Why? |
| Male | 27 | 2021 | 367725 | 0.15 | Why? |
| Coronary Disease | 1 | 2021 | 645 | 0.14 | Why? |
| Metals | 1 | 2016 | 182 | 0.14 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.14 | Why? |
| Blood Proteins | 1 | 2018 | 551 | 0.14 | Why? |
| Gene Editing | 1 | 2018 | 330 | 0.14 | Why? |
| Aged | 19 | 2021 | 215776 | 0.14 | Why? |
| Chest Pain | 1 | 2019 | 578 | 0.14 | Why? |
| Prosthesis Design | 4 | 2017 | 594 | 0.14 | Why? |
| Sleep Apnea Syndromes | 1 | 2017 | 282 | 0.13 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.13 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.13 | Why? |
| Feasibility Studies | 2 | 2020 | 3467 | 0.13 | Why? |
| Renal Insufficiency | 1 | 2021 | 810 | 0.13 | Why? |
| Sofosbuvir | 1 | 2018 | 518 | 0.13 | Why? |
| Cardiovascular Agents | 2 | 2017 | 663 | 0.13 | Why? |
| Carotid Artery Diseases | 1 | 2016 | 251 | 0.13 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.13 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2018 | 422 | 0.13 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2019 | 552 | 0.12 | Why? |
| Fellowships and Scholarships | 1 | 2021 | 931 | 0.12 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.12 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.12 | Why? |
| Death, Sudden, Cardiac | 1 | 2017 | 522 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2018 | 471 | 0.12 | Why? |
| Program Development | 1 | 2018 | 1089 | 0.11 | Why? |
| Ultrasonography, Interventional | 1 | 2016 | 560 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.11 | Why? |
| Hypertension, Pulmonary | 1 | 2021 | 970 | 0.11 | Why? |
| Nurse's Role | 1 | 2019 | 614 | 0.11 | Why? |
| Dogs | 1 | 2019 | 2529 | 0.11 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.11 | Why? |
| Needs Assessment | 1 | 2021 | 2352 | 0.11 | Why? |
| Nitric Oxide | 1 | 2018 | 769 | 0.11 | Why? |
| Heart Transplantation | 1 | 2021 | 1293 | 0.11 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.10 | Why? |
| Recombination, Genetic | 1 | 2017 | 1265 | 0.10 | Why? |
| Ventricular Dysfunction, Left | 1 | 2018 | 993 | 0.10 | Why? |
| Ventricular Function, Left | 1 | 2018 | 1555 | 0.10 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.09 | Why? |
| Registries | 5 | 2019 | 12327 | 0.09 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.09 | Why? |
| Time Factors | 8 | 2019 | 31397 | 0.09 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.09 | Why? |
| Proteome | 1 | 2018 | 1812 | 0.09 | Why? |
| Heart | 1 | 2018 | 1791 | 0.09 | Why? |
| Receptors, Adrenergic, beta | 1 | 2007 | 19 | 0.09 | Why? |
| Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 16 | 0.09 | Why? |
| Female | 19 | 2021 | 380317 | 0.09 | Why? |
| Muscle Cells | 1 | 2007 | 40 | 0.09 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Thrombolytic Therapy | 1 | 2019 | 2218 | 0.08 | Why? |
| Treatment Outcome | 9 | 2019 | 51732 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Clinical Competence | 1 | 2021 | 3263 | 0.08 | Why? |
| Fibrinolytic Agents | 1 | 2018 | 1702 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.07 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.07 | Why? |
| Sleep | 1 | 2017 | 2695 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.07 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.06 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2019 | 5883 | 0.06 | Why? |
| Adult | 5 | 2021 | 244371 | 0.06 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.06 | Why? |
| Calcium | 1 | 2007 | 708 | 0.06 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| HMGA1a Protein | 1 | 2018 | 5 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.05 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.04 | Why? |
| Eligibility Determination | 1 | 2019 | 255 | 0.04 | Why? |
| Atrioventricular Block | 1 | 2018 | 105 | 0.04 | Why? |
| Cellular Reprogramming | 1 | 2018 | 117 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.04 | Why? |
| Angina Pectoris | 1 | 2017 | 114 | 0.04 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Biomedical Technology | 1 | 2018 | 257 | 0.03 | Why? |
| Genome, Human | 1 | 2018 | 400 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Monitoring, Ambulatory | 1 | 2017 | 343 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2018 | 763 | 0.03 | Why? |
| Single-Blind Method | 1 | 2016 | 1283 | 0.03 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.03 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2016 | 665 | 0.03 | Why? |
| Safety | 1 | 2018 | 1583 | 0.03 | Why? |
| Tomography, Optical Coherence | 1 | 2017 | 1008 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Isoproterenol | 1 | 2007 | 31 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2019 | 3755 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Cell Death | 1 | 2007 | 536 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Phosphorylation | 1 | 2007 | 1060 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Europe | 1 | 2019 | 12702 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| Databases, Factual | 1 | 2016 | 6248 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 13720 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.00 | Why? |
Indolfi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(238)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_